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Methods: We performed a single case longitudinal study of a patient who was subsequently found to
have a novel A705fs mutation in the TBK1 gene. Hewas assessed annually over a 7-year period with a
series of clinical, cognitive, and magnetic resonance imaging assessments. His brain underwent path-
ological examination at postmortem.
Results: The patient presented at the age of 64 years with an 18-month history of personality change
including increased rigidity and obsessiveness, apathy, loss of empathy, and development of a sweet
tooth. His mother had developed progressive behavioral and cognitive impairment from the age of
57 years. Neuropsychometry revealed intact cognition at first assessment. Magnetic resonance imag-
ing showed focal right temporal lobe atrophy. Over the next few years his behavioral problems pro-
gressed and he developed cognitive impairment, initially with anomia and prosopagnosia.
Neurological examination remained normal throughout without any features of motor neurone dis-
ease. He died at the age of 72 years and postmortem showed TDP-43 type A pathology but with
an unusual novel feature of numerous TAR DNA-binding protein 43 (TDP-43)–positive neuritic
structures at the cerebral cortex/subcortical white matter junction. There was also associated argyr-
ophilic grain disease not previously reported in other TBK1 mutation cases.
Discussion: TBK1-associated FTD can be associated with right temporal variant FTD with progres-
sive behavioral change and relatively intact cognition initially. The case further highlights the benefits
of next-generation sequencing technologies in the diagnosis of neurodegenerative disorders and the
importance of detailed neuropathologic analysis.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Frontotemporal dementia (FTD) is a frequent cause of
young-onset dementia with around one-third of cases being
familial. Patients may present clinically with behavioral oreimer’s Association. This is an open access article under the CC BY license
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oping motor neurone disease (MND). Mutations in several
genes have been linked to FTD and MND with C9orf72 be-
ing the most commonly associated gene. However, recent
studies have identified mutations in the TANK-binding ki-
nase 1 (TBK1) as a novel cause of both FTD and MND
[1–5]. Patients with TBK1 mutations have been described
with the clinical syndrome of FTD (usually the behavioral
variant), MND (usually amyotrophic lateral sclerosis), or
the combination of both [6], but few details are currently
known about the clinical phenotype, atrophy pattern, and
time-course of the disease. In this study, we present a longi-
tudinal case report of a patient with a novel TBK1 mutation
assessed over several years.2. Methods
The patient had consented to be part of a longitudinal
study at the Dementia Research Centre, UCL Institute of
Neurology, approved by the Local Ethics Committee. As
part of the study he underwent a standardized clinical history
and examination, neuropsychometric testing, and three-
dimensional T1-weighted magnetic resonance imaging
(MRI), initially on a 1.5GE Signa scanner (first four scans)
and then on a 3T Siemens Trio scanner. Using the volumetric
MRI, we calculated cortical volumes using an automated
segmentation method as previously described [7]. We also
manually segmented the caudate, hippocampus, amygdala,
and hypothalamus [8–10]. All brain volumes were
corrected for total intracranial volume, which was
calculated using SPM12 (www.fil.ion.ucl.ac.uk/spm). We
used the SPM12 Serial Longitudinal Registration tool to
estimate the percentage of volumetric contraction and
expansion for each voxel across the different follow-up
visits.
The patient consented to brain donation and after death
his brain was assessed using standard pathological methods
at the Queen Square Brain Bank for Neurological Disorders,
UCL Institute of Neurology. Tissue sections of 7-mm thick-
ness were immunostained using commercially available an-
tibodies to the following proteins: TDP-43 (1:800; 2E2-D3;
Abnova); p62 (1:200; BD Transduction Laboratories, Ox-
ford, UK); ubiquitin (1:200; Dako, Ely, UK); a-synuclein
(1:1000; 42/syn; BD Biosciences), tau (1:600; AT8;
Thermo), or Ab (1:100; 6F/3D; DAKO) as previously
described [11]. Briefly, immunohistochemistry for all anti-
bodies required pressure cooker pretreatment in citrate
buffer, pH 6.0. Endogenous peroxidase activity was blocked
with 0.3% H2O2 in methanol and nonspecific binding with
10% dried milk solution. Tissue sections were incubated
with the primary antibodies, followed by biotinylated anti-
mouse immunoglobulin G (1:200, 30 minutes; DAKO) and
ABC complex (30 minutes; DAKO). Color was developed
with diaminobenzidine/H2O2.
The patient was tested for mutations in the C9orf72 gene
and also using a panel examining 17 genes linked to neuro-degeneration (APP, CHMP2B, CSF1R, FUS, GRN, ITM2B,
MAPT, NOTCH3, PRNP, PSEN1, PSEN2, SERPINI1,
SQSTM1, TARDBP, TREM2, TYROBP, and VCP) [12].
These were negative. Whole-exome sequencing was subse-
quently carried out using the Agilent SureSelect Human
All Exon v2 target enrichment kit (Agilent, Santa Clara,
CA) followed by paired-end sequencing performed on an Il-
lumina HiSeq2000 (Illumina, San Diego, CA), achieving an
average 30-fold depth-of-coverage of target sequence. After
trimming and quality control, sequencing reads were aligned
to the human reference genome (hg19) using Burrows-
Wheeler Aligner [13], followed by variant calling and reca-
libration by Genome Analysis Toolkit [14] and annotation
with SnpEff [15]. Variants of interest were validated by
Sanger sequencing. This revealed a novel 13 base pair dele-
tion causing a frameshift mutation in the TBK1 gene
(c.G2114del-CTGAAAATAACCA; p.A705fs).3. Results
A retired right-handed gentleman presented at the age of
64 years with an 18-month history of personality change
including increased rigidity and obsessiveness, apathy, loss
of empathy, and development of a sweet tooth. His mother
had developed progressive behavioral and cognitive impair-
ment from the age of 57 years but without a formal diag-
nosis. At his first assessment his Mini-Mental State
Examination was 30/30 and neuropsychometry revealed
intact cognition (Table 1). Over the next few years his behav-
ioral problems progressed with worsening of his initial
symptoms and the development of disinhibition. His cogni-
tion also started to become impaired: by 2 years after his
initial visit he had developed anomia and prosopagnosia,
with impairment on tests of naming and face memory
(Table 1). Over the next few visits he subsequently devel-
oped impairment of executive function and verbal episodic
memory, followed by visuoperceptual problems, and finally
impaired single word comprehension and dyscalculia
(Table 1). Neurological examination remained normal
throughout without any features of MND. He died at the
age of 72 years after 9 years of illness.
His initial MRI scan showed evidence of focal right tem-
poral lobe atrophy, particularly affecting the anterior tempo-
ral lobe and the amygdala (Table 1, Fig. 1). Over a period of
time, atrophy spread from the right temporal lobe to involve
the right frontal lobe (particularly the orbitofrontal cortex),
and more posteriorly to involve the right posterior temporal
lobe, hippocampus, and anterior parietal lobe. Subcortical
involvement including the caudate and hypothalamus was
also seen (Table 1). Atrophy progressed over time to involve
the left hemisphere, following a similar pattern to the right,
focused initially on the anterior and medial temporal lobe
(Fig. 1). However, atrophy remained asymmetrical
throughout the disease process, being greater on the right
than on the left side (Table 1, Fig. 1).
Table 1
Longitudinal neuropsychometric and neuroimaging measures
Cognitive and imaging measures Initial visit 1 y 2 y 1 m 3 y 2 m 4 y 11 m* 5 y 11 m 6 y 11 m
Neuropsychometry
Mini-Mental State Examination 30 30 30 28 24 NT 23
Wechsler Abbreviated Scale of
Intelligence Total IQ score
NT NT 75%–95% 75%–95% 25%–50% 25%–50% 5%–10%
Episodic memory
Recognition Memory Test for Words 95% 95% 75% NT 10%–25% ,5% ,5%
Recognition Memory Test for Faces 50%–75% 50% 5%–10% NT ,5% ,5% ,5%
California Verbal Learning Test Delay
Recall
75% 75%–95% 50% NT NT NT NT
California Verbal Learning Test Delay
Recognition
75%–95% 75%–95% 75%–90% NT NT NT NT
Language
Graded Naming Test 50%–75% 50%–75% 5%–10% NT ,5% ,5% ,5%
British Picture Vocabulary Scale NT NT NT NT 50%–75% ,5% ,5%
Synonyms Task NT NT 95% 10%–25% NT NT NT
National Adult Reading Test 75%–95% 75%–95% 75%–95% NT 75%–95% 25%–50% 25%–50%
Calculation
Graded Difficulty Arithmetic Test NT NT NT 95% 95% 95% 75%–95%
Visuoperceptual skills
Visual Object and Space Perception
battery: Object Decision subtest
NT NT 75%–95% 50%–75% 25%–50% 5%–10% ,5%
Attention and executive function
D-KEFS Color-Word Interference Test
Color Naming NT NT NT NT 25%–50% ,5% ,5%
Word Reading NT NT NT NT 50%–75% 25%–50% 50%–75%
Ink-Color Naming NT NT NT NT 50%–75% ,5% 25%–50%
Trail Making Test Part A 10%–25% 10%–25% 10%–25% 5%–10% NT NT NT
Trail Making Test Part B 10%–25% 50%–75% 25%–50% 25%–50% NT NT NT
Wechsler Memory Scale-Revised Digit
Span Forward
NT NT NT NT 50%–75% 25%–50% 25%–50%
Wechsler Memory Scale-Revised Digit
Span Backward
NT NT NT NT 50%–75% 50%–75% 50%–75%
Neuroimaging
Cortical volumes (% of TIV)
Frontal
Right 5.3 5.2 5.3 5.1 4.9 NA NA
Left 5.5 5.5 5.5 5.4 5.2 NA NA
Temporal
Right 3.2 3.1 2.9 2.8 2.8 NA NA
Left 3.7 3.6 3.5 3.3 3.2 NA NA
Insula
Right 0.33 0.29 0.28 0.26 0.26 NA NA
Left 0.38 0.36 0.33 0.30 0.31 NA NA
Subcortical volumes (% of TIV)
Caudate
Right 0.17 0.16 0.15 0.12 0.10 NA NA
Left 0.17 0.18 0.16 0.15 0.13 NA NA
Hippocampus
Right 0.13 0.13 0.12 0.10 0.09 NA NA
Left 0.13 0.13 0.12 0.11 0.10 NA NA
Amygdala
Right 0.056 0.056 0.040 0.041 0.032 NA NA
Left 0.069 0.064 0.052 0.047 0.039 NA NA
Hypothalamus
Right 0.029 0.021 0.019 0.016 0.016 NA NA
Left 0.030 0.023 0.024 0.019 0.017 NA NA
Abbreviations: NA, not analyzable; NT, not tested; D-KEFS, Delis-Kaplan Executive Function System; TIV, total intracranial volume.
NOTE. For neuropsychometric measures, scores are given as percentiles. For neuroimaging measures, volumes of regions are given as a percentage of TIV.
*For fifth visit, neuropsychometry was performed at 4 years 11months from baseline andmagnetic resonance imaging scanwas performed at 5 years 1month.
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Fig. 1. (A) Coronal sections of T1 volumetric magnetic resonance imaging scans at baseline and at the following four follow-up visits. In the lower panels, a
close-up of the amygdala shows progressive asymmetrical medial temporal lobe atrophy. (B) Coronal sections at the level of the frontal (top) and mid-temporal
lobes (second row), axial section through the orbitofrontal and medial temporal lobe (third row), and sagittal section through the right hemisphere (bottom). The
first column represents the baseline scan with the four columns to the right showing a longitudinal SPM overlay (in comparison with the baseline scan) with
yellow/red representing 5% or greater volumetric contraction and blue representing 5% or greater volumetric expansion. At the first follow-up scan atrophy is
localized to the right temporal lobe and orbitofrontal lobe, but over time spreads dorsally and posteriorly, involving the frontal lobe, posterior temporal lobe, and
similar areas in the contralateral hemisphere.
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Fig. 2. Macroscopic and microscopic pathological features. Enlargement of the lateral ventricle was evident (A, double arrow) and severe atrophy of the tem-
poral lobe (A, arrow). The substantia nigra showed severe pallor (B, arrow). TDP-43 immunohistochemistry highlighted occasional neuronal cytoplasmic in-
clusions in the granule cell layer of the hippocampus (C, arrow). Neuronal cytoplasmic inclusions (D, arrow) and short neuropil threads (D, double arrow) were
also observed in the gray matter of the temporal cortex and many short curved dystrophic neurites were seen in the white matter (E). Tau immunohistochemistry
showed coiled bodies in the temporal white matter (F, arrow), argyrophilic grains in the subiculum (G), and neurofibrillary tangles in the granule cell layer of the
hippocampus (H). Bar in C represents 40 mm in C, E, and H and 60 mm in D, F, and G.
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atrophy, which was more severe in the temporal lobe than
the frontal lobe (Fig. 2A) with severe reduction in the bulk
of the amygdala and hippocampus, and evidence of hippo-
campal sclerosis. The substantia nigra showed severe pallor
(Fig. 2B), and the locus coeruleus was also pale. The brain-
stem and cerebellum appeared normal. Microscopically, the
normal neocortical hexalaminar architecture was variably
disrupted by spongiosis and nerve cell loss across the cortex.
This was mild atrophy in the prefrontal cortex but severe in
the anterior cingulate gyrus and very severe in the temporalcortex with a clear gradient toward the medial temporal lobe
structures. Accordingly, the fusiform gyrus and the parahip-
pocampus were the most severely affected regions showing
severe nerve cell loss and an advanced spongy state. a-Syn-
uclein and Ab immunohistochemical preparations were
negative throughout all areas and no “star-like” p62-
positive granular inclusions were seen in the granule cells
of the dentate fascia or the cerebellum. TDP-43 immunohis-
tochemistry demonstrated a mixture of different lesions in
the cortical areas, including neuronal cytoplasmic inclu-
sions, short curved dystrophic neurites, and coiled bodies
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TDP-43–positive neuritic structures and also oligodendrog-
lial inclusions at the cerebral cortex/subcortical white matter
junction (Fig. 2E). Only occasional TDP-43–positive
neuronal cytoplasmic inclusions were seen in the granule
cells of the dentate fascia (Fig. 2C) and only occasional
neuritic structures in the amygdala. TDP-43–positive inclu-
sions corresponded to frontotemporal lobar degeneration
(FTLD)-TDP type A pathology. Lower motor neurons
were investigated in the 12th nerve nucleus for TDP-43 pa-
thology: no pathological inclusions were seen and normal
TDP-43 immunohistochemistry was observed with TDP-
43 found in the nucleus, i.e. there was no pathological evi-
dence of MND. Tau immunohistochemistry demonstrated
not only occasional neuropil threads (NTs) in the prefrontal
and parietal cortices but also neurofibrillary tangles, pretan-
gles, NTs, and coiled bodies (Fig. 2F) in the temporal cortex,
particularly in the medial temporal region. Severe tau pa-
thology was observed in the hippocampal formation and par-
ahippocampus, where pretangles and NTs were seen
throughout and grain-like structures observed in the subicu-
lum (Fig. 2G) consistent with argyrophilic grain disease.
Pretangles and neurofibrillary tangles were seen in the
granule cells of the dentate fascia (Fig. 2H). Tau-positive
coiled bodies, NTs, and an occasional tufted astrocyte-like
structure were seen in the pontine tegmentum. There was
minimal Purkinje cell loss in the cerebellar cortex and occa-
sional NTs were present in the dentate nucleus.4. Discussion
We describe the clinical, cognitive, and neuroanatomical
progression over 9 years of a patient with FTD due to a novel
TBK1 mutation who was found to have FTLD-TDP type A
pathology. This case highlights a number of important and
novel aspects of TBK1 mutations as well as the description
of a novel mutation, it also reveals the clinical and neuroan-
atomical phenotype that can be associated with TBK1 muta-
tions, and the nature of disease progression.
The 13 base pair deletion causes a frameshift introducing
a premature stop codon and is therefore likely to be patho-
genic even in the absence of supporting segregation or func-
tional data. Haploinsufficiency is a known disease
mechanism for TBK1, and loss-of-function mutations in
TBK1 have already been described in patients with FTD,
MND, and FTD-MND [1–5].
The most common clinical phenotype associated with
TBK1 mutations is FTD-MND rather than FTD alone, with
the frequency in patient cohorts 3.0% to 4.5% and 0.5% to
1.1%, respectively [3,4]. However, despite close clinical
follow-up, our patient exhibited no signs of MND. In terms
of the specific FTD phenotype, most patients described in
the literature so far have presented with behavioral variant
FTD (bvFTD), rather than the language variant, consistent
with the case here, although there appears to be a high prev-
alence of early memory impairment [3,6]. Despite ourpatient complaining of subjective cognitive symptoms
early in the disease, his neuropsychometric testing
remained normal initially with the development of anomia
and prosopagnosia only a few years into the illness. The
disease duration in our patient was 9 years with an onset at
63 years, which is not dissimilar from findings of a recent
study showing a mean onset of 66.3 years and a disease
duration of 8.2 years [6].
Previous studies have not detailed the neuroanatomical
phenotype of TBK1mutations. Here, we have shown an asso-
ciation with right temporal lobe atrophy. This anatomical
variant of FTD has been found to be caused by a number of
pathologies, with patients presenting with bvFTDmore likely
to have tau pathology, and those with the semantic dementia
phenotype likely to have TDP-43 pathology [16,17]. Here, we
describe a casewith bvFTDwho has FTLD-TDP typeA and a
TBK1 mutation, a novel association with right temporal lobe
variant FTD. Progression of atrophy over time was consistent
with a number of other right temporal lobe cases who remain
with an asymmetrical pattern of involvement but develop a
similar pattern of focal temporal lobe involvement in the
opposite temporal lobe as the disease progresses.
Little is known about the neuropathology of TBK1 muta-
tions but previous cases have shown either FTLD-TDP type
A or type B pathology, with the histological findings in our
case being consistent with type A. Although it fits criteria for
this subtype, therewere nonetheless some unusual novel fea-
tures with the presence of numerous TDP-43–positive
neuritic structures at the cerebral cortex/subcortical white
matter junction. This case also had associated tau pathology
consistent with argyrophilic grain disease, which has not
been seen in other TBK1 mutation cases.
Further research is needed to understand the complete
phenotype of patients with TBK1 mutations but it should
be considered as a cause of right temporal variant FTD,
and in patients who present with familial FTD, whether
MND is present or not.Acknowledgments
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1. Systematic review: TBK1 mutations have recently
been linked to frontotemporal dementia (FTD). To
put our findings into context, we reviewed the litera-
ture on Pubmed Central relating to other published
TBK1 cases and research.
2. Interpretation: Our findings detail the natural long-
term progression in a case of TBK1-associated FTD
and further characterize the related neuropathologic
findings. In addition, the case emphasizes the bene-
fits of next-generation sequencing technologies in
the diagnosis of neurodegenerative disorders.
3. Future directions: Further functional studies of TBK1
and other genes linked to neurodegenerative diseases
are needed to fully comprehend how loss-of-function
and other mutations affect cellular pathways and
cause disease.
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